Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.

In all models, the interaction between medication and time remained highly significant (p <0.01, Supplementary Tables 5a-d ), supporting that there was both a difference in the effect of medication type on LS and that there was a difference in the change in LS over time between groups.

also in 132,142 other papers

Baseline ascites did not have a significant effect on GFR, yet there was a trend towards significance for baseline albumin ( Supplementary Table 3a ).

also in 2,760 other papers